IRX-2 ADMINISTRATION

ADMINISTRATION OF IRX-2 AS PART OF THE NEOADJUVANT REGIMEN

In head and neck squamous cell carcinoma, the IRX-2 biologic is injected into the mastoid region and drains into the lymphatic vessels, where physiologic quantities of IRX-2 restore the lymph node microenvironment and enable dendritic cells (DCs) to activate T cells against endogenous tumor peptides that have drained to the lymph node.

To promote uptake of endogenous tumor peptides by DCs and subsequent T-cell activation during the first treatment cycle, the dose of IRX-2 is divided and injected bilaterally subcutaneously (SC) into the mastoid region during neoadjuvant treatment.

Regional Administration of IRX-2 as Part of the Neoadjuvant Regimen

ADMINISTRATION OF IRX-2 AS PART OF THE BOOSTER REGIMEN

During the IRX-2 Booster Regimen, when the objective is to amplify and expand an ongoing immune response, the dose of IRX-2 is divided and injected bilaterally subcutaneously into the deltoid region.

© 2016 IRX Therapeutics